| Outcome Measures: |
Primary: Proportion of cured patients in the sitagliptin group versus the proportion of cured patients in the empagliflozin group, The primary efficacy endpoint will be evaluated as clinical cure after 12 weeks of addition of sitagliptin or empagliflozin to metformin and after 12 weeks after adding empaglifozin to sitagliptin group and vise versa. Clinical cure defined by A1C controlled (less than 7%), decrease in fasting and postprandial plasma glucose (mg/dl)., After completion of the study (One year anticipated) | Secondary: The decrease in the body weight in patients in sitagliptin group versus empagliflozin group, The decreased in body weight (Kg) from the baseline measures after therapy., After completion of the study (One year anticipated)|The decrease in blood pressure in patients in sitagliptin group versus empagliflozin group, decrease in blood pressure is defined as the decrease in SBP and/or DBP (mmHg) from the baseline measures after completing therapy, After completion of the study (One year anticipated)|The change in lipid profile in patients in sitagliptin group versus empagliflozin group, Change in lipid profile including decreasing in the following measures from the baseline measures after therapy is completed: low density lipoprotein (mg/dl), total cholesterol (mg/dl), triglyceride (mg/dl) and high density lipoprotein (mg/dl)., After completion of the study (One year anticipated) | Other: Percentage of adverse effects appeared in patients in sitagliptin group versus percentage of adverse effects appear in patients in the empagliflozin group., AEs (n%) included all events with an onset after the first dose of open label emoagliflozin or sitagliptin and up to 7 days after the last dose of study drug. AEs of special interest included hypoglycaemia, genitourinary infections, hypersensitivity reactions, diabetic ketoacidosis, acute pancreatitis, hypotension, and dehydration. Confirmed hypoglycemic AEs were defined as events with a plasma glucose concentration of ≤ 3.9 mmol/L., After completion of the study (One year anticipated)
|
